Bluejay Diagnostics Stock (NASDAQ:BJDX)

Revenue Ownership Financials Chart

Previous Close

$1.56

52W Range

$1.46 - $37.50

50D Avg

$1.69

200D Avg

$3.27

Market Cap

$2.42M

Avg Vol (3M)

$794.18K

Beta

0.47

Div Yield

BJDX Company Profile

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Nov 10, 2021

Website

BJDX Performance

BJDX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	$249.04K
Operating Income	-	$-10.31M	$-9.32M
Net Income	$-7.72M	$-9.95M	$-9.23M
EBITDA	-	$-9.17M	$-8.99M
Basic EPS	$-42.08	$-72.62	$-73.22
Diluted EPS	$-42.08	$-72.62	$-73.22

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
BFRI	Biofrontera Inc.
BBLG	Bone Biologics Corporation
TNON	Tenon Medical, Inc.
TIVC	Tivic Health Systems, Inc.
CNTX	Context Therapeutics Inc.
KTTA	Pasithea Therapeutics Corp.